by Richard Daverman, PhD
August 25, 2012 -- Joincare Pharma will invest $157 million to increase its production of carbapenem antibiotics; the Chengdu Institute of Biological Products licensed technology to facilitate production of conjugate vaccines from Fina Biosolutions of Maryland; Golden Meditech will distribute in China a ThermoGenesis device that separates stem cells from cord blood; Tigermed Consulting signed a letter of intent to provide MSD China with clinical trial services for three years; PRA International, a global CRO, opened a second office in China; China’s revised Essential Drug List is now expected to include 700 drugs, up from 307 drugs currently; FortuneRock of the US received SFDA approval to begin China clinical trials of its long-acting formulation of Interferon-a2a; and Biostar Pharma received an Army New Drug Certificate for Zushima Analgesic Spray, a topical pain relief treatment. More details….
Stock Symbols: (SHA: 600380) (HK: 801; TW: 910801) (NSDQ: KOOL) (SHE: 300347) (NSDQ GM: BSPM)
